Brussels, Belgium

Aline Van Pel


Average Co-Inventor Count = 6.0

ph-index = 9

Forward Citations = 267(Granted Patents)


Company Filing History:


Years Active: 1994-2013

Loading Chart...
24 patents (USPTO):Explore Patents

Title: Aline van Pel: Pioneering Contributions to Cancer Research

Introduction: Aline van Pel, located in Brussels, Belgium, is a distinguished inventor with a remarkable portfolio of 19 patents. Van Pel's work focuses on advancements in cancer research, particularly in the development of tumor rejection antigens and related biotechnologies.

Latest Patents: Among Aline van Pel's most notable patents are those related to tumor rejection antigens, including one that comprises polypeptides with an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2. These polypeptides exhibit an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1. Another significant patent involves isolated tumor rejection antigen precursor proteins, specifically MAGE-2 and MAGE-3. This invention includes an isolated DNA sequence that codes for an antigen expressed by tumor cells, which is recognized by cytotoxic T cells, resulting in the lysis of the tumor. Furthermore, it encompasses cells transfected by this DNA sequence and highlights various therapeutic and diagnostic applications.

Career Highlights: Van Pel's professional journey is marked by significant contributions to the field of cancer research. He has been affiliated with the Ludwig Institute for Cancer Research Limited and the Ludwig Institute, where he has played a crucial role in advancing our understanding of tumor immunology.

Collaborations: Throughout his career, Aline van Pel has collaborated with esteemed colleagues such as Etienne De Plaen and Thierry R Boon-Falleur. These partnerships have been instrumental in fostering innovative research and development in cancer therapies.

Conclusion: Aline van Pel remains a prominent figure in the realm of cancer research, with 19 patents that illustrate his commitment to innovation and discovery. His groundbreaking work in developing tumor rejection antigens continues to pave the way for new therapeutic approaches, showcasing the vital role of inventors in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…